{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:04:37Z","timestamp":1789635877233,"version":"4.0.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["NU62PS924762-01"],"award-info":[{"award-number":["NU62PS924762-01"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study aimed to describe the current hepatitis C virus (HCV) continuum of care and characterize the prevalence of HCV among Seattle-area people who inject drugs (PWID), including an assessment of changes between 2018 and 2022. Cross-sectional data from the 2018 and 2022 Seattle-area National HIV Behavioral Surveillance (NHBS) surveys of PWID was included in this study. All participants completed a biobehavioral survey and were offered rapid HIV and HCV antibody testing. Among those who screened HCV antibody-positive, we estimated proportions for steps along the HCV care continuum, including proportions of PWID who had previously been told they had HCV, were treated, and cured. The 2018 and 2022 NHBS-PWID surveys included 533 and 495 participants, respectively. In 2022, 61% (303\/495) of PWID tested HCV antibody-positive, compared with 71% (376\/533) in 2018. Among those who were HCV antibody-positive, prior HCV testing was common in both years [94% (95% CI: 91%-96%) in 2018; 92% (95% CI: 89%-95%) in 2022]. The proportion reporting prior HCV diagnosis increased from 68% (95% CI: 63%-72%) in 2018 to 71% (95% CI: 66%-76%) in 2022. Among those diagnosed, treatment rose from 26% (95% CI: 20%-31%) in 2018 to 47% (95% CI: 40%-54%) in 2022, and cure increased from 18% (95% CI: 14%-23%) in 2018 to 33% (95% CI: 27%-40%) in 2022. Compared to 2018, in 2022 the proportion of PWID with HCV in the Seattle area who had been treated and cured nearly doubled. Sustained investment in HCV diagnosis and treatment is needed to strengthen the HCV continuum of care.<\/jats:p>","DOI":"10.1007\/s10461-026-05110-9","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:44:39Z","timestamp":1775040279000},"page":"2731-2738","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Increases in Hepatitis C Virus (HCV) Treatment and Cure Among People Who Inject Drugs in the Seattle Area Between 2018 and 2022"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6696-8898","authenticated-orcid":false,"given":"Jenni L.","family":"Ebersberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0877-5399","authenticated-orcid":false,"given":"Judith I.","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4935-5166","authenticated-orcid":false,"given":"Maria A.","family":"Corcorran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2076-3083","authenticated-orcid":false,"given":"Sara N.","family":"Glick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"5110_CR1","unstructured":"World Health Organization. Hepatitis C [Internet]. WHO. 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed 9 April 2024"},{"issue":"8","key":"5110_CR2","doi-asserted-by":"publisher","first-page":"e0309345","DOI":"10.1371\/journal.pone.0309345","volume":"19","author":"H Mazumder","year":"2024","unstructured":"Mazumder H, Hossain MF, Shrestha P, Mahmud S, Husain M, et al. Prevalence and associated risk factors of current hepatitis C infection among U.S. general population and injection drug users aged 20\u201359 years: NHANES 2009\u20132018. PLoS One. 2024;19(8):e0309345.","journal-title":"PLoS One"},{"issue":"3","key":"5110_CR3","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.30297","volume":"69","author":"MG Hofmeister","year":"2019","unstructured":"Hofmeister MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW, et al. Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013\u20132016. Hepatology. 2019;69(3):1020\u201331. https:\/\/doi.org\/10.1002\/hep.30297. Epub 2018 Nov 6. PMID: 30398671; PMCID: PMC6719781.","journal-title":"Hepatology"},{"issue":"10","key":"5110_CR4","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1111\/liv.14634","volume":"40","author":"O Falade-Nwulia","year":"2020","unstructured":"Falade-Nwulia O, Gicquelais RE, Astemborski J, McCormick SD, Kirk G, Sulkowski M, et al. Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era. Liver Int. 2020;40(10):2407\u201316. https:\/\/doi.org\/10.1111\/liv.14634. PMID: 32770638; PMCID: PMC7706292.","journal-title":"Liver Int"},{"key":"5110_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108797","volume":"225","author":"A Hotton","year":"2021","unstructured":"Hotton A, Mackesy-Amiti ME, Boodram B. Trends in homelessness and injection practices among young urban and suburban people who inject drugs: 1997\u20132017. Drug Alcohol Depend. 2021;225:108797. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108797.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"5110_CR6","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.aohep.2018.12.003","volume":"18","author":"NA Mukhtar","year":"2019","unstructured":"Mukhtar NA, Ness EM, Jhaveri M, Fix OK, Hart M, Dale C, et al. Epidemiologic features of a large hepatitis C cohort evaluated in a major health system in the western United States. Ann Hepatol. 2019;18(2):360\u20135. https:\/\/doi.org\/10.1016\/j.aohep.2018.12.003.","journal-title":"Ann Hepatol"},{"issue":"1","key":"5110_CR7","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.20.1.22146","volume":"20","author":"J Grebely","year":"2017","unstructured":"Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there? J Int AIDS Soc. 2017;20(1):22146. https:\/\/doi.org\/10.7448\/IAS.20.1.22146.","journal-title":"J Int AIDS Soc"},{"key":"5110_CR8","unstructured":"Basit H, Tyagi I, Koirala J, Hepatitis C, [Internet] SP. 2023.\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430897\/. Accessed 6 March 2023"},{"key":"5110_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.drugalcdep.2018.11.026","volume":"195","author":"JI Tsui","year":"2019","unstructured":"Tsui JI, Miller CM, Scott JD, Corcorran MA, Dombrowski JC, Glick SN. Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle. Drug Alcohol Depend. 2019;195:114\u201320. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.11.026.","journal-title":"Drug Alcohol Depend"},{"key":"5110_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108525","volume":"220","author":"MA Corcorran","year":"2021","unstructured":"Corcorran MA, Tsui JI, Scott JD, Dombrowski JC, Glick SN. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington. Drug Alcohol Depend. 2021;220:108525. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108525.","journal-title":"Drug Alcohol Depend"},{"key":"5110_CR11","doi-asserted-by":"publisher","first-page":"100213","DOI":"10.1016\/j.dadr.2023.100213","volume":"10","author":"JI Tsui","year":"2023","unstructured":"Tsui JI, Gojic AJ, Pierce KA, Tung EL, Connolly NC, Radick AC, et al. Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs. Drug Alcohol Depend Rep. 2023;10:100213. PMID: 38261893; PMCID: PMC10796962.","journal-title":"Drug Alcohol Depend Rep"},{"issue":"6","key":"5110_CR12","first-page":"667","volume":"28","author":"MP Cooper","year":"2022","unstructured":"Cooper MP, Foley H, Damico D, Wright M, Rhudy C, Schadler A, et al. Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy. J Manag Care Spec Pharm. 2022;28(6):667\u201372. PMID: 35621721; PMCID: PMC10372976.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"5110_CR13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12875-024-02507-0","volume":"25","author":"P Cox-North","year":"2024","unstructured":"Cox-North P, Wiggins L, Stockton J, Huriaux E, Fliss M, Evaskus L, et al. Provider reported implementation barriers to hepatitis C elimination in Washington State. BMC Prim Care. 2024;25(1):252. https:\/\/doi.org\/10.1186\/s12875-024-02507-0. PMID: 38992590; PMCID: PMC11241921.","journal-title":"BMC Prim Care"},{"issue":"11","key":"5110_CR14","doi-asserted-by":"publisher","DOI":"10.2196\/39053","volume":"8","author":"D Kanny","year":"2022","unstructured":"Kanny D, Broz D, Finlayson T, Lee K, Sionean C, Wejnert C, et al. A key comprehensive system for biobehavioral surveillance of populations disproportionately affected by HIV (National HIV Behavioral Surveillance): cross-sectional survey study. JMIR Public Health Surveill. 2022;8(11):e39053. https:\/\/doi.org\/10.2196\/39053.","journal-title":"JMIR Public Health Surveill"},{"issue":"7","key":"5110_CR15","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1007\/s10461-017-1827-1","volume":"22","author":"J Li","year":"2018","unstructured":"Li J, Valente TW, Shin HS, Weeks M, Zelenev A, Moothi G, et al. Overlooked Threats to Respondent Driven Sampling Estimators: Peer Recruitment Reality, Degree Measures, and Random Selection Assumption. AIDS Behav. 2018;22(7):2340\u201359. https:\/\/doi.org\/10.1007\/s10461-017-1827-1. PMID: 28660381; PMCID: PMC5745307.","journal-title":"AIDS Behav"},{"key":"5110_CR16","unstructured":"Centers for Disease Control and Prevention. HIV infection risk, prevention, and testing behaviors among persons who inject drugs\u2014National HIV behavioral surveillance, 20, Cities US. 2022. HIV Surveillance Special Report 35. https:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance.html. Published February 2024. Accessed Feb 2026."},{"key":"5110_CR17","unstructured":"Washington State Department of Health. Hep C Free Washington Urgent: Test and treat people who use drugs for hepatitis C [Internet]. Washington State Healthcare Authority; February 2021. DOH 150\u2009\u2013\u2009146.\u00a0https:\/\/doh.wa.gov\/sites\/default\/files\/legacy\/Documents\/Pubs\/\/150-146-HepC-cliniciantestingbrief.pdf. Accessed Feb 2021."},{"key":"5110_CR18","unstructured":"Washington State Healthcare Authority. Washington State Health Care Authority and partners reach milestone toward eliminating hepatitis C [Internet]. 2024 May 15. https:\/\/www.hca.wa.gov\/about-hca\/news\/news-release\/washington-state-health-care-authority-and-partners-reach-milestone-toward-eliminating-hepatitis-c#:~:text=In%202019%2C%20HCA%20contracted%20with,Apple%20Health%20(Medicaid)%20clients. Accessed 15 May 2024."},{"key":"5110_CR19","doi-asserted-by":"publisher","first-page":"103706","DOI":"10.1016\/j.drugpo.2022.103706","volume":"105","author":"H Valerio","year":"2022","unstructured":"Valerio H, Alavi M, Conway A, Silk D, Treloar C, Martinello M, et al. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study. Int J Drug Policy. 2022;105:103706. Epub 2022 May 6. PMID: 35533635.","journal-title":"Int J Drug Policy"},{"key":"5110_CR20","doi-asserted-by":"publisher","first-page":"104044","DOI":"10.1016\/j.drugpo.2023.104044","volume":"116","author":"KB Malme","year":"2023","unstructured":"Malme KB, Ulstein K, Finbr\u00e5ten AK, W\u00fcsthoff LEC, Kielland KB, Hauge J, et al. Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study. Int J Drug Policy. 2023;116:104044. Epub 2023 May 5. PMID: 37149914.","journal-title":"Int J Drug Policy"},{"key":"5110_CR21","doi-asserted-by":"publisher","first-page":"111007","DOI":"10.1016\/j.drugalcdep.2023.111007","volume":"253","author":"CR Coyle","year":"2023","unstructured":"Coyle CR, Gicquelais RE, Genberg BL, Astemborski J, Falade-Nwulia O, Kirk GD, et al. Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals. Drug Alcohol Depend. 2023;253:111007. Epub 2023 Oct 21. PMID: 38456165; PMCID: PMC10917145.","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"5110_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293315","volume":"18","author":"K Gnanapandithan","year":"2023","unstructured":"Gnanapandithan K, Ghali MP. Self-awareness of hepatitis C infection in the United States: a cross-sectional study based on the National Health Nutrition and Examination Survey. PLoS One. 2023;18(10):e0293315. https:\/\/doi.org\/10.1371\/journal.pone.0293315.","journal-title":"PLoS One"},{"issue":"1","key":"5110_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-16017-8","volume":"23","author":"CR Balsom","year":"2023","unstructured":"Balsom CR, Farrell A, Kelly DV. Barriers and enablers to testing for hepatitis C virus infection in people who inject drugs - a scoping review of the qualitative evidence. BMC Public Health. 2023;23(1):1038. https:\/\/doi.org\/10.1186\/s12889-023-16017-8.","journal-title":"BMC Public Health"},{"issue":"Suppl 9","key":"5110_CR24","doi-asserted-by":"publisher","first-page":"S773","DOI":"10.1093\/infdis\/jiaa574","volume":"222","author":"SB Trooskin","year":"2020","unstructured":"Trooskin SB, Dore G, Kostman J. We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States. J Infect Dis. 2020;222(Suppl 9):S773\u201381. https:\/\/doi.org\/10.1093\/infdis\/jiaa574.","journal-title":"J Infect Dis"},{"key":"5110_CR25","unstructured":"Washington State Department of Health. Hep C Free Washington: Plan to Eliminate Hepatitis C in Washington State by 2030 [Internet]. Division of disease control & health statistics. 2019 July. 150-nonDOH. https:\/\/doh.wa.gov\/sites\/default\/files\/legacy\/Documents\/Pubs\/150nonDOH-HepCFreeWA-PlanJuly2019.pdf. Accessed July 2019."}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05110-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-026-05110-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05110-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:35:51Z","timestamp":1789634151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-026-05110-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5110"],"URL":"https:\/\/doi.org\/10.1007\/s10461-026-05110-9","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"19 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Retrospective Open Access has been updated.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Co-author SNG has received research funding from Cepheid for work that is unrelated to this study. All other authors have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}